Dermatology · Evidence depth: moderate

Mohs Micrographic Surgery

Extremely high.

Ownership-sensitivity model

The 10 vectors of a physician career.

Every path is scored 0-100 across 10 critical dimensions using public-data signals, modeled assumptions, and verification prompts. Modeled estimate. Not a salary survey. See methodology.

95/100

Income ceiling

Income ceiling

One of the absolute highest ceilings in all of clinical medicine.

The reality

Mohs surgery billing is incredibly lucrative because you legally bill for both the surgical excision and the pathology reading.

The signal

The throughput is massive; a highly efficient Mohs surgeon does 6-10 cases (often multiple stages each) a day.

The catch

In-house lab ownership acts as a massive multiplier on the professional fees.

The verdict

An absolute money-printing machine, provided the internal referral network is ironclad.

90/100

Lifestyle control

Lifestyle control

Exceptional control; highly predictable surgical days.

The reality

The practice is 100% outpatient, elective, and scheduled weeks in advance.

The signal

You have immense power to control the pace of your clinic and the number of cases you book.

The catch

There are absolutely no hospital rounds and no emergent surgeries to disrupt your evening.

The verdict

The most lucrative pure-lifestyle surgical specialty available.

Premium analysis

8 more dimensions scored, with the reasoning behind each

See plans and unlock

The scores are below. Premium adds what sits behind each one: the claim, the signal supporting it, the limitation that weakens it, and what it should change about your decision.

  • Sleep / call burdenLower is better5/100
  • Ownership / facility upsideHigher is better85/100
  • Geography flexibilityHigher is better75/100
  • Innovation / industry adjacencyHigher is better20/100
  • Training opportunity costLower is better50/100
  • Job-market densityHigher is better75/100
  • Malpractice / litigation pressureLower is better40/100
  • Burnout-mismatch riskLower is better30/100

Scores are modeled from the specialty module's evidence and are estimates, not measurements. Confidence and data depth are labeled inside every premium card.

DoctorCalculator modeled income structure

Derived model. Directional

Modeled base range

$560k - $710k

Derm's flagship procedure lane; biopsy-to-closure economics under one roof.

Production upside

$765k - $955k

Biopsy-to-closure under one roof: high fixed lab overhead, exceptional per-case margin at volume.

Ownership upside

Very high

Mohs lab ownership (slides read in-house), ASC/office suites, and referral-network equity.

Salary-only gap

High

A salaried Mohs surgeon gives up the lab technical component and same-roof closure economics.

Modeled estimate. Not a salary survey. Derived model. Directional only. Verify against real offers, contracts, and local mentors. Income scales with payer mix, ownership, and geography. See methodology.

Want the code-level view behind numbers like these? Open the RVU calculator for this specialty's procedures, CMS times, and locality-adjusted Medicare rates.

External benchmark reference

Verify independently

~$600k

External benchmark reference - verify independently. Not ingested DoctorCalculator source data.

Private group

Best fit

  • The Procedure-Heavy Wealth Builder. Top-tier income through volume, procedures, production, and ownership.
  • The Lifestyle-First Clinician. A good life on sane hours, and the math actually works.

Poor fit

  • The Acute-Care Identity Seeker. Energized by intensity, emergencies, and high-stakes work.

Premium detail

Common regrets on this path

See plans and unlock

2 documented regrets for this path, each with the burnout driver behind it and the question to verify it against a real schedule before you commit. Written from field notes on this specialty, not generic career advice.

This path is described at validated confidence (Evidence depth: moderate). Detailed evidence cards are added as the module is validated; we will not manufacture precision before then.